QURE - uniQure plunges 27% on Q2 revenue miss postpones higher dose trial of Huntington's disease therapy

• uniQure ( NASDAQ: QURE ) is trading 27% down premarket after the company reported lower-than-expected Q2 revenue.
• The company also announced that it was postponing the trial of a higher dose of AMT-130 to treat Huntington’s disease  procedures due to recent suspected unexpected severe adverse reactions.
• In July, the company reported to the health authorities suspected unexpected severe adverse reactions in three of the 14 patients treated with the higher dose of AMT-130.
• However, the company said lower-dose procedures were not affected and it continues to expect on anticipated data readouts in 2023.
• Revenue fell ~100% to $0.5M, and missed estimates by $8.71M, while a loss of -$0.84 beat by $0.11.
• Cost of contract revenues for the quarter was nil compared to $23.2M, a year earlier.
• Research and development expenses were $46.2M compared to $32.8M, due to preclinical development of temporal lobe epilepsy (AMT-260) advancing the clinical development of the company’s Huntington’s disease gene therapy program, and recruitment of personnel to support the development of product candidates.

For further details see: